Oncology Biomarker Database Includes Cancer Companion Diagnostic Pathway

A comprehensive cancer biomarker database has been launched that can help in finding new diagnostic, prognostic, and companion diagnostic biomarkers.

The database includes cancer companion-diagnostics biomarker pathway maps. It contains more than 8,500 discovery phase, preclinical, or clinical cancer biomarkers that were identified or validated using patient derived samples.

Sciclips (Madison, MI, USA) launched the database, which covers a wide variety of biomarkers such as blood cancer biomarkers (peripheral blood, plasma, serum etc), tumor biomarkers, urinary cancer biomarkers, fecal cancer biomarkers, saliva cancer biomarkers, breath cancer biomarkers, etc.

More than 100 types of cancer are included in the cancer biomarker database. For each cancer type, the biomarkers are classified into diagnostic biomarkers; for the diagnostics application, disease predictive/risk assessment biomarkers; for predicting the risk or genetic susceptibility in developing cancer; drug efficacy/response biomarkers; biomarkers for studying the efficacy of anticancer drug treatments, including predictive biomarkers and prognostic biomarkers; and for determining the clinical outcome in cancer patients.

The types of cancer biomarkers include protein biomarkers, miRNA biomarkers, single-nucleotide polymorphism (SNP) biomarkers, gene expression biomarkers, epigenetic biomarkers, and metabolomic biomarkers.

With the growing trend of personalized healthcare concept and advance in biomarker research, there is a need for development of innovative personalized cancer drugs with companion biomarker assays to identify the most appropriate cancer patient, tumor type, and disease state.

Patient/sample details, experimental results, observations, biological and molecular functional analysis, biological process analysis, protein-protein interaction networks of each biomarker are listed in the database.

The pathway maps will help to identify new anticancer drug predictive and response biomarkers, for the discovery of new drug targets with improved efficacy or targeted therapy to overcome side effects, patient stratification, developing personalized strategies for monitoring cancer progression, treatment, diagnosis, and prognosis.

Related Links:
Sciclips